NEPHROPLUS Nephrocare Health Services Q4 FY26 results (Jan–Mar 2026) and concall
Nephroplus delivered a strong Q4 and FY26, with significant revenue and profit growth driven by operational leverage, international expansion, and improved capital efficiency. While Q4 margins were impacted by a one-time ECL provision, the underlying performance remained robust. The company continues to focus on its core dialysis business, leveraging its India platform for global expansion, and maintaining a positive outlook with a 15-20% revenue CAGR guidance for the medium term.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 21.5%, net profit up 20.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 197 | 219 | 228 | 246 | 260 +32% | 266 +21% |
| EBITDA | 44 | 51 | 48 | 64 | 61 +39% | 51 +0% |
| Net profit | 20 | 25 | 24 | -9 | 32 +60% | 30 +20% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
